Brain cancer boost: radioactive tile added to standard therapy in new trial

NCT ID NCT05342883

Ongoing Disease control Sponsor: GT Medical Technologies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor removal, then start standard chemoradiation within 21–35 days. The goal is to see if this combination can improve local tumor control without delaying standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GammaTile (cesium-131 brachytherapy device) and temozolomide
What this could lead to: If successful, this approach could improve local control of glioblastoma and potentially extend survival when added to standard treatment.
What could go wrong: This is a small, single-arm pilot study focused on feasibility and safety, not yet designed to prove efficacy. Adding radiation may increase side effects without clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Advent Health Orlando

Orlando, Florida, 32803, United States
Brown University Health

Providence, Rhode Island, 02906, United States
ECU Health Medical Center - Vidant

Greenville, North Carolina, 27834, United States
Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital

Tampa, Florida, 33606, United States
Henry Ford Health System

Detroit, Michigan, 48202, United States
HonorHeath Scottsdale Osborn Medical Center

Scottsdale, Arizona, 85251, United States
Indiana University Office of Clinical Research

Indianapolis, Indiana, 46202, United States
Keck Medicine of USC

Los Angeles, California, 90033, United States
Kettering Medical Center

Kettering, Ohio, 45429, United States
Piedmont Healthcare

Atlanta, Georgia, 30309, United States
RUSH University

Chicago, Illinois, 60607, United States
St. Louis University Hospital Center

St Louis, Missouri, 63110, United States
UC Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
UTHealth Houston | Memorial Hermann Health System

Houston, Texas, 77030, United States
University of Kansas Hospital

Kansas City, Kansas, 66016, United States
University of Minnesota

Minneapolis, Minnesota, 55485, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.